AstraZeneca Says Datopotamab Deruxtecan Showed Numerical Overall Survival Benefit Over Docetaxel In TROPION-Lung01 Trial, But Did Not Reach Statistical Significance; No OS Improvement Observed
AstraZeneca Says Datopotamab Deruxtecan Showed Numerical Overall Survival Benefit Over Docetaxel In TROPION-Lung01 Trial, But Did Not Reach Statistical Significance; No OS Improvement Observed
阿斯利康表示，達託帕坦慶達黴素在TROPION-Lung01試驗中顯示出總體生存期數字上的益處，但未達到統計學意義；未觀察到生存期改善
AstraZeneca Says Datopotamab Deruxtecan Showed Numerical Overall Survival Benefit Over Docetaxel In TROPION-Lung01 Trial, But Did Not Reach Statistical Significance; No OS Improvement Observed
阿斯利康表示，在Tropion-Lung01試驗中，Datopotamab Deruxtecan在數字上顯示出與多西他賽相比的總體生存益處，但未達到統計學意義；未觀察到操作系統改進
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。